Long non-coding RNA SPRY4-IT1 promotes cell proliferation and invasion by regulation of Cdc20 in pancreatic cancer cells

Wenhao Guo¹*, Kunhong Zhong², Heng Wei², Chunlai Nie², Zhu Yuan²*

¹ Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China, ² Lab of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

* wenhaoguo2011@163.com (WG); yuanzhu@scu.edu.cn (ZY)

Abstract

Accumulating evidence has demonstrated that long non-coding RNAs (lncRNAs) play a critical role in the development of human cancers including pancreatic cancer. Long non-coding RNA SPRY4-IT1 (sprouty4-intron transcript 1) has been reported to play an oncogenic role in various types of human carcinomas. However, the role of SPRY4-IT1 in pancreatic cancer is unclear. The objective of this study was to determine the function of SPRY4-IT1 on proliferation and invasion in pancreatic cancer. In the current study, we dissected the function and mechanism of SPRY4-IT1 by multiple approaches including Real-time RT-PCR, Western blotting analysis, MTT assay, Wound healing assay, Transwell assay, and transfection. We found that down-regulation of SPRY4-IT1 inhibited cell growth and induced cell apoptosis in pancreatic cancer cells. Moreover, SPRY4-IT1 knockdown induced cell cycle arrest at G0/G1 phase. Furthermore, inhibition of SPRY4-IT1 retarded cell migration and invasion in pancreatic cancer cells. Overexpression of SPRY4-IT1 enhanced cell growth and invasion, and inhibited cell apoptosis in pancreatic cancer cells. Mechanistically, suppression of SPRY4-IT1 inhibited the expression of Cdc20 in pancreatic cancer cells. Our findings demonstrated that inhibition of SPRY4-IT1 could be a potential therapeutic approach for the treatment of pancreatic cancer.

Introduction

Pancreatic cancer is one of the highly aggressive tumors in human [1]. The expected numbers of new pancreatic cancer cases and deaths in 2017 in the United States are 53,670 and 43,090, respectively [2]. The five-year relative survival rate is currently 8% in the United States. This low rate is partly because more than one-half of pancreatic cancer patients are diagnosed at a distant stage [2]. Although several treatment strategies including surgery of tumor resection, chemotherapy, and immunotherapy have been used, the outcomes of pancreatic cancer patients are still bad [3, 4]. Thus, it is highly urgent to explore the molecular mechanism of
pancreatic cancer progression and to find the new therapeutic targets for the treatment of pancreatic cancer.

Emerging evidence has revealed that long non-coding RNAs (lncRNAs), a subgroup of noncoding RNAs, play a critical role in the development of human cancers including pancreatic cancer [5]. It has been known that lncRNAs are longer than 200 nucleotides, but have little or no function of protein-coding capacity [6]. Recent studies have demonstrated that lncRNAs govern gene expression via chromosome remodeling, transcription and post-transcriptional processes. Therefore, lncRNAs could regulate multiple cellular precisions including proliferation, apoptosis, cell cycle, migration, and invasion [7]. Without a doubt, abnormal expression of lncRNAs could contribute to tumor development and progression [8]. In line with this, lncRNAs have been reported to play pivotal roles in various types of human carcinomas including SPRY4-IT1 [8, 9]. It has been documented that SPRY4-IT1 is transcribed from the second intron of the SPRY4 gene [9]. Accumulating evidence has suggested that SPRY4-IT1 plays an oncogenic role in human cancers [9]. However, the role of SPRY4-IT1 in pancreatic cancer is unclear. In this study, we determined the function of SPRY4-IT1 in the regulation of proliferation, apoptosis, cell cycle, migration and invasion in pancreatic cancer. We further explored the potential mechanism of SPRY4-IT1-mediated tumor progression. Our findings suggest that inhibition of SPRY4-IT1 could be a potential therapeutic approach for the treatment of pancreatic cancer.

**Results**

**Down-regulation of LncRNA SPRY4-IT1 inhibited cell growth**

To explore the function of SPRY4-IT1 in pancreatic cancer cells, BxPC-3 and PANC-1 cells were transfected with SPRY4-IT1 siRNA to down-regulate the expression of SPRY4-IT1. The efficacy of SPRY4-IT1 siRNA transfection was validated by real-time RT-PCR. Our results showed that SPRY4-IT1 siRNA significantly reduced the SPRY4-IT1 expression in both pancreatic cancer cell lines (Fig 1A). To determine whether SPRY4-IT1 plays a role on cell growth, we conducted MTT assay in pancreatic cancer cells after SPRY4-IT1 siRNA transfection. We found that down-regulation of SPRY4-IT1 inhibited cell growth in both BxPC-3 and PANC-1 cells. Our results further demonstrated that SPRY4-IT1 siRNA 1 exhibited cell growth inhibition at greater degree. Therefore, we used SPRY4-IT1 siRNA 1 for our following further studies.

**Down-regulation of LncRNA SPRY4-IT1 induced cell apoptotic death**

To further determine whether SPRY4-IT1 could induce cell apoptosis, Annexin V-FITC/PI and FACS were used to measure the percentage of cell apoptotic death in pancreatic cancer cells after SPRY4-IT1 siRNA transfection. We observed that the percentage of apoptotic cells was reduced in BxPC-3 and PANC-1 cells transfected with SPRY4-IT1 siRNA (Fig 2A). This result suggested that down-regulation of SPRY4-IT1 induced cell apoptosis in pancreatic cancer cells.

**Down-regulation of LncRNA SPRY4-IT1 induced cell cycle arrest**

To further define how SPRY4-IT1 regulated cell growth, PI staining and flow cytometry were used to measure the cell cycle phases in pancreatic cancer cells after SPRY4-IT1 siRNA transfection. Our data showed that the percentage of G0/G1 phase was increased from 56.31% to 74.26% in BxPC-3 cells after SPRY4-IT1 siRNA transfection (Fig 2B). Similarly, the proportion of G0/G1 phase was increased from 53.92% in control group to 76.69% in SPRY4-IT1 siRNA

PLOS ONE | https://doi.org/10.1371/journal.pone.0193483 | February 28, 2018 | 2 / 13
transfected PANC-1 cells (Fig 2B). These data revealed that down-regulation of SPRY4-IT1 induced cell cycle arrest into G0/G1 phase in pancreatic cancer cells.

**Down-regulation of LncRNA SPRY4-IT1 inhibited cell migration and invasion**

To determine whether SPRY4-IT1 could regulate cell migration in pancreatic cancer cells, a scratch wound-healing assay was performed in BxPC-3 and PANC-1 cells transfected with
SPRY4-IT1 siRNA. We observed that down-regulation of SPRY4-IT1 inhibited cell migration in both pancreatic cancer cell lines (Fig 3A). To further validate the function of SPRY4-IT1 on cell invasion, we measured cell invasive activity using Transwell inserts with Matrigel. Our results from invasion assay showed that SPRY4-IT1 siRNA treatment suppressed cell invasion in pancreatic cancer cells (Fig 3B). Altogether, suppression of SPRY4-IT1 inhibited cell motility activity.

To further confirm the function of SPRY4-IT1 in pancreatic cancer cells, we overexpressed SPRY4-IT1 in BxPC-3 and PANC-1 cells using recombinant lentiviruses containing full length SPRY4-IT1 (Fig 4A). We found that overexpression of SPRY4-IT1 promoted cell growth in both pancreatic cancer cell lines (Fig 4A). Moreover, overexpression of SPRY4-IT1 inhibited cell apoptosis in pancreatic cancer cells (Fig 4B). Furthermore, up-regulation of SPRY4-IT1 promoted cell migration and invasion in both pancreatic cancer cell lines (Fig 5B and 5C). Overexpression of SPRY4-IT1 enhanced cell cycle progression (Fig 5D). Taken together, SPRY4-IT1 plays an oncogenic role in pancreatic cancer cells.

SPRY4-IT1 regulated Cdc20 expression
To reveal the potential molecular mechanism of SPRY4-IT1 in pancreatic cancer cells, we measured the expression of Cdc20 (cell division cycle 20) using Western blotting analysis. We found that downregulation of SPRY4-IT1 inhibited the expression of Cdc20 in BxPC-3 and PANC-1 cells (Fig 6A and 6B, S1 Fig). In line with this, overexpression of SPRY4-IT1 increased Cdc20 expression in pancreatic cancer cells (Fig 6A and 6B, S1 Fig).
Depletion of Cdc20 decreased cell growth and invasion caused by SPRY4-IT1

Next, to further investigate whether Cdc20 was involved in SPRY4-IT1-mediated tumor progression, we performed a rescue assay. SPRY4-IT1 and Cdc20 shRNA were simultaneously transfected into BxPC-3 cells. We observed that Cdc20 expression is reduced in SPRY4-IT1-transfected cells after Cdc20 shRNA infection (Fig 6C and S1 Fig). Our MTT assay results showed that depletion of Cdc20 decreased cell growth caused by SPRY4-IT1 upregulation (Fig 7A). Furthermore, Cdc20 down-regulation enhanced cell apoptosis in SPRY4-IT1-transfected cells (Fig 7B). Moreover, Transwell chambers assay results demonstrated that silencing of Cdc20 inhibited cell invasion induced by SPRY4-IT1 upregulation (Fig 7B). These findings suggested that SPRY4-IT1 could promote tumor progression via regulation of Cdc20 in pancreatic cancer cells.

Discussion

In the present study, we investigated the biological function of SPRY4-IT1 on cell proliferation, cell cycle, apoptosis, and motility activity in pancreatic cancer cells. We found that down-regulation of SPRY4-IT1 inhibited cell growth and induced cell cycle arrest at G0/G1 phase as well as cell apoptosis in pancreatic cancer cells. Consistently, upregulation of SPRY4-IT1 promoted cell growth and inhibited apoptosis. Moreover, SPRY4-IT1 inhibited cell migration and invasion, while overexpression of SPRY4-IT1 enhanced cell motility activity. Mechanistically, suppression of SPRY4-IT1 inhibited the expression of Cdc20, whereas overexpression of SPRY4-IT1 increased Cdc20 level in pancreatic cancer cells. Our findings indicated that SPRY4-IT1 exerts its function in part through regulation of Cdc20 in pancreatic cancer.

A line of evidence suggests that SPRY4-IT1 was critically involved in tumorigenesis [10]. For example, some studies have shown that SPRY4-IT1 was up-regulated in a variety of human cancers including esophageal squamous cell carcinoma (ESCC) [11], renal cancer...
More importantly, SPRY4-IT1 overexpression was associated with poor prognosis in various types of human malignancies such as renal cancer [12], ESCC [11], gastric cancer [14], bladder cancer [15], HCC (hepatocellular carcinoma) [16]. For instance, increased SPRY4-IT1 expression was reported to be associated with a larger tumor size and an advanced pathological stage in breast cancer patients [13]. SPRY4-IT1 levels were highly positively correlated with tumor size, TNM stage, invasion depth, distant metastasis, and reduced OS (overall survival) and DFS (disease-free survival) in gastric cancer [14]. Recently, Zhou et al reported that SPRY4-IT1 was concerned with the poor prognosis and contributed to the progression of thyroid cancer [22]. These reports suggest that SPRY4-IT1 plays an oncogenic role in human cancers.

Recent studies have revealed that knockdown of SPRY4-IT1 led to defects in cell growth, differentiation, and higher rates of apoptosis in melanoma cell lines [23]. Similarly, SPRY4-IT1 down-regulation reduced cell proliferation in vitro and in vivo in ESCC cells [11]. In line with this, depletion of SPRY4-IT1 reduced renal cancer cell proliferation, migration and invasion [12]. The elevated expression of SPRY4-IT1 increased rate of wound closure in melanoma cells.
Knockdown of SPRY4-IT1 reduced cell invasiveness and migration in ESCC cells [23]. In the present study, for the first time, we reported that SPRY4-IT1 enhanced cell proliferation, migration and invasion in pancreatic cancer cells. Therefore, down-regulation of SPRY4-IT1 could be useful for treating patients with pancreatic cancer.

**Fig 6. Effect of SPRY4-IT1 on the expression of Cdc20.** (A) The Cdc20 mRNA level was measured by real-time RT-PCR in pancreatic cancer cells after SPRY4-IT1 siRNA or cDNA transfection. CS: Control siRNA; SS: SPRY4-IT1 siRNA. CP: Control plasmid; SP: SPRY4-IT1 plasmid. (B) The Cdc20 protein level was measured by Western blotting analysis in cells after SPRY4-IT1 siRNA or SPRY4-IT1 cDNA transfection. (C) The Cdc20 expression was measured by Western blotting analysis in cells after SPRY4-IT1 cDNA transfection plus Cdc20 shRNA infection.

https://doi.org/10.1371/journal.pone.0193483.g006
Multiple studies have unraveled that SPRY4-IT1 regulated its downstream targets to exert its function. Sun et al reported that EZH2 (enhancer of zeste homolog 2)-mediated epigenetic suppression of SPRY4-IT1 promoted cell proliferation and metastasis through regulation of EMT (epithelial-mesenchymal transition) in NSCLC (non-small cell lung cancer) cells [24]. Interestingly, SPRY4-IT1 promoted tumor cell proliferation and invasion through activation of EZH2 in HCC [25]. Overexpression of SPRY4-IT1 promoted EMT via the regulation of E-cadherin and vimentin expression in NSCLC cells [24], ESCC cells [26, 27], colorectal cancer [18, 28], and ovarian cancer cells [29]. In keeping with this report, knockdown of SPRY4-IT1 suppressed glioma cell proliferation, metastasis and EMT [30]. Moreover, SPRY4-IT1 promoted EMT through association with Snail1 in osteosarcoma [31]. SPRY4-IT1 knockdown induced apoptosis via lipin2-mediated alterations in lipid metabolism in melanoma cells [32]. SPRY4-IT1 increased the proliferation through upregulation of ZNF703 expression in human breast cancer cells [13]. SPRY4-IT1 promoted cell proliferation, migration and invasion partially through regulation of certain cyclins and MMPs (matrix metalloproteinases)-related genes in gastric cancer [14]. Yu et al found that SPRY4-IT1 promoted development of hepatic cellular carcinoma via interacting with ERRα and predicted poor prognosis [33]. Recent study showed that SPRY4-IT1 sponged miR-101-3p to promote proliferation and metastasis through upregulation of EZH2 in bladder cancer cells and colorectal cancer cells [34, 35]. In the current study, we identified that SPRY4-IT1 could upregulate the expression of Cdc20 oncoprotein in pancreatic cancer. Higher expression of Cdc20 has been observed in a variety of human cancers and is correlated with poor prognosis [36]. Therefore, SPRY4-IT1 could

Fig 7. Effect of SPRY4-IT1 on the cell apoptosis and invasion. (A) Apoptotic cell death was measured using Annexin V-FITC/PI method in cells after SPRY4-IT1 cDNA transfection plus Cdc20 shRNA infection for 48 hours. SP: SPRY4-IT1 plasmid; SP+DS: SPRY4-IT1 plus Cdc20 shRNA. (B) Cell invasion was measured using Transwell inserts with Matrigel in cells after SPRY4-IT1 cDNA transfection plus Cdc20 shRNA infection for 24 hours. SP: SPRY4-IT1 plasmid; SP+DS: SPRY4-IT1 plus Cdc20 shRNA.

https://doi.org/10.1371/journal.pone.0193483.g007
exert its oncogenic function in part via upregulation of Cdc20. Without a doubt, further in-depth explore whether SPRY4-IT1 is a valuable target for therapeutic intervention in pancreatic cancer is required.

Materials and methods

Cell culture and reagents
BxPC-3 (K-ras wild-type, p53 and p16 mutants, Rb positive) and PANC-1 (K-ras mutant, p53 and p16 mutants, Rb positive) cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in DMEM containing 10% fetal bovine serum at 37°C in 5% CO2 humidified incubator. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] are obtained from Sigma (St. Louis, MO, USA). Anti-Cdc20, anti-tubulin, and the secondary antibodies were purchased from Cell Signaling Technology Company.

Cell tranfection
BxPC-3 and PANC-1 cells were seeded in six-well plates and transfected with lncRNA SPRY4-IT1 siRNA or the scrambled siRNA as the negative control using lipofectamine 2000 according to manufacturer’s instructions [37]. The siRNA negative control: GGC TAC GTC CAG GAG GC G A, SPRY4-IT1 siRNA 1: CCC AGA ATG TTG ACA GCT GCC TCT T, SPRY4-IT1 siRNA 2: TGG AGG GTT ATG GGA GCC TGT GAA T. The recombinant lentiviruses containing full length SPRY4-IT1 and the nonspecific control were obtained from GenePharma Company (Shanghai, China). The alterations of SPRY4-IT1 in pancreatic cancer cells were validated by real-time PCR.

Quantitative reverse transcription-PCR
Total RNA in transfected pancreatic cancer cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. Then, RNA was reverse-transcribed into complementary DNA by the Reverse cDNA synthesis kit. Real-time PCR was conducted on the ABI 7500 cycler using SYBR Green PCR kit. The primer sequences were as following: SPRY4-IT1: forward 5'-AGC CAC ATA AAT TCA GCA GA-3', reverse 5'-GAT GTA GGA TTC CTT TCA-3'; Cdc20, forward primer 5'-GAC CAC TCC TAG CAA ACC TGG -3', reverse primer 5'-GGG CGT CTG GCT GTT TTC A-3'.

MTT assay
The transfected cells (5 x 10^3) were seeded in 96-well culture plates. At the indicated time points, the cells were treated with MTT by adding it to the medium. Cells were incubated at 37°C for 4 hours and then the medium was removed. DMSO was added for 30 minutes to lyse the cells. Optical density (OD) was measured at 490 nm using a micro-plate reader [38].

Cell apoptosis assay
The transfected pancreatic cancer cells were cultured in 6-well plates for 48 hours. Then, cells were harvested and resuspended in 500μl binding buffer with 5μl Propidium iodide (PI) and 5μl FITC-conjugated anti-Annexin V antibody. Apoptosis was measured using a FACScalibur flow cytometer (BD, USA) as described before [38].
Cell cycle analysis

The transfected pancreatic cancer cells were seeded in a six-well plate for overnight. After 48 hours, cells were harvested, washed and resuspended in 70% cold alcohol and kept at 4°C overnight. Then, cells were suspended in 1 × 10^6 cells/ml in PBS. Subsequently, cells were incubated with 0.1mg/ml RNase I and 50 mg/ml PI at 37˚C for 30 min. Cell cycle was further detected with a FACScalibur flow cytometer (BD, USA).

Wound healing assay

The transfected cells were seeded in 6-well plates for 48 hours. After the cells get 100% gather, the cell monolayer in each well was scraped using a 200 µl pipette tip to generate a wound. Photographic images were taken by using microscope from each well at 0 h, 10 h or 20 h post-injury time points.

Invasion assay

The invasion assay was conducted in transfected pancreatic cancer cells by 24-well Transwell inserts with Matrigel coating. Specifically, cells were seeded into the upper chamber of an 8µm pore size insert. The cells were allowed to invade the bottom chamber containing 10% FBS. After incubation for 24h, the invasive cells attached to the lower membrane surface were fixed with 4% paraformaldehyde and stained with Giemsa solution and 4 µg/mL calcein AM, respectively. The stained invasive cells were photographed.

Western blotting assay

To determine the expression of Cdc20 in transfected pancreatic cancer cells, we conducted Western blotting analysis. The cells were lysed in the cold lysis buffer in the presence aprotinin, leupeptin, PMSF, and phosphatase inhibitor cocktails II and III (Sigma) The protein extracts were separated on SDS-PAGE and transferred to PVDF membrane. The membrane was incubated with indicated antibodies and detected using an enhanced chemiluminescence kit as described previously [37]. The anti-Cdc20 (1:1000), anti-tubulin (1:2500), and the secondary antibodies (1:3000) were used in this assay.

Statistical analysis

All the statistical analyses were performed using GraphPad Prism 4.0 (Graph pad Software, La Jolla, CA) by Student’s test. All the data were expressed as mean ± SD (standard deviation). Moreover, p<0.05 was considered statistically significant.

Supporting information

S1 Fig. Original images for Fig 6B and 6C.

(DOCX)

Acknowledgments

We thank our colleague for their critical comments to improve our manuscript.

Author Contributions

Conceptualization: Wenhao Guo.
Data curation: Wenhao Guo, Heng Wei.
Investigation: Wenhao Guo, Kunhong Zhong, Heng Wei, Chunlai Nie.

Methodology: Heng Wei.

Supervision: Wenhao Guo, Zhu Yuan.

Validation: Kunhong Zhong, Zhu Yuan.

Visualization: Chunlai Nie.

Writing – original draft: Wenhao Guo.

Writing – review & editing: Chunlai Nie, Zhu Yuan.

References

1. Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol. 2017; 116(1):25–34. Epub 2017/06/08. https://doi.org/10.1002/jso.24623 PMID: 28591993.

2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30. Epub 2017/01/06. https://doi.org/10.3322/caac.21367 PMID: 28055103.

3. Ramos MC, Bouliaiz H, Grinan-Lison C, Marchal JA, Vicente F. What’s new in treatment of pancreatic cancer: a patent review (2010–2017). Expert Opin Ther Pat. 2017;1:1–16. Epub 2017/07/01. https://doi.org/10.1080/13543776.2017.1349106 PMID: 28665163.

4. Arolti F, Zaniboni A. Immunotherapy for pancreatic cancer: present and future. Immunotherapy. 2017; 9(7):607–16. Epub 2017/06/10. https://doi.org/10.2217/imt-2016-0142 PMID: 28595517.

5. Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15):3965–81. Epub 2017/07/14. https://doi.org/10.1158/0008-5472.CAN-16-2634 PMID: 28701486.

6. Blythe AJ, Fox AH, Bond CS. The ins and outs of lncRNA structure: How, why and what comes next? Biochim Biophys Acta. 2016; 1859(1):46–58. Epub 2015/09/02. https://doi.org/10.1016/j.bbagrm.2015.08.009 PMID: 26325022.

7. Zeng S, Xiao YF, Tang B, Hu CJ, Xie R, Yang SM, et al. Long Noncoding RNA in Digestive Tract Cancers: Function, Mechanism, and Potential Biomarker. Oncologist. 2015; 20(8):898–906. Epub 2015/07/15. https://doi.org/10.1634/theoncologist.2014-0475 PMID: 26156325.

8. Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014; 1839(11):1097–109. Epub 2014/08/28. https://doi.org/10.1016/j.bbagen.2014.08.012 PMID: 25159663.

9. Li J, Chen Y, Chen Z, He A, Xie H, Zhang Q, et al. SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers. Tumour Biol. 2017; 39(6):1010428317711406. Epub 2017/06/28. https://doi.org/10.1177/1010428317711406 PMID: 28651500.

10. Zhong Y, Chen Z, Guo S, Liao X, Xie H, Zheng Y, et al. TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017; 96(46):e8583. Epub 2017/11/18. https://doi.org/10.1097/MD.0000000000008583 PMID: 29145271.

11. Xie HW, Wu QQ, Zhu B, Chen FJ, Ji L, Li SQ, et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol. 2014; 35(8):7743–54. Epub 2014/05/09. https://doi.org/10.1007/s13277-014-2013-y PMID: 24810925.

12. Zhang HM, Yang FQ, Yan Y, Che JP, Zheng JH. High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2014; 7(9):5801–9. Epub 2014/10/23. PMID: 25337221.

13. Shi Y, Li J, Liu Y, Ding J, Fan Y, Tian Y, et al. The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol Cancer. 2015; 14:51. Epub 2015/03/10. https://doi.org/10.1186/s12943-015-0318-0 PMID: 25742952.

14. Peng W, Wu G, Fan H, Wu J, Feng J. Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour Biol. 2015; 36(9):6751–8. Epub 2015/04/04. https://doi.org/10.1007/s13277-015-3376-4 PMID: 25835973.

15. Zhao XL, Zhao ZH, Xu WC, Hou JQ, Du XY. Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Int J Clin Exp Pathol. 2015; 8(2):1954–60. Epub 2015/05/24. PMID: 25973068.

16. Jing W, Gao S, Zhu M, Luo P, Jing X, Chai H, et al. Potential diagnostic value of IncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol Rep. 2016; 36(2):1085–92. Epub 2016/06/10. https://doi.org/10.3892/or.2016.4859 PMID: 27278245.
Ru N, Liang J, Zhang F, Wu W, Wang F, Liu X, et al. SPRY4 Intronic Transcript 1 Promotes Epithelial-Mesenchymal Transition. Tumour Biol. 2016; 37(8):10871–6. Epub 2016/06/17. https://doi.org/10.1007/s13277-016-4962-9 PMID: 26683252.

20. Cui F, Wu D, He X, Wang W, Xi J, Wang M. Long noncoding RNA SPRY4-IT1 promotes esophageal squamous cell carcinoma cell proliferation, invasion, and epithelial-mesenchymal transition. Tumour Biol. 2016; 37(8):10871–6. Epub 2016/06/17. https://doi.org/10.1007/s13277-016-4962-9 PMID: 26683252.

21. Zhou Y, Wang DL, Pang Q. Long noncoding RNA SPRY4-IT1 is a prognostic factor for poor overall survival and has an oncogenic role in glioma. Eur Rev Med Pharmacol Sci. 2016; 20(14):3035–9. Epub 2016/07/28. PMID: 27460732.

22. Cao D, Ding Q, Yu W, Gao M, Wang Y. Long noncoding RNA SPRY4-IT1 promotes malignant development of colorectal cancer by targeting epithelial-mesenchymal transition. Onco Targets Ther. 2016; 9:5417–25. Epub 2016/09/14. https://doi.org/10.2147/OTT.S11794 PMID: 27621655.

23. Tan W, Song ZZ, Xu Q, Qu X, Li Z, Wang Y, et al. Up-Regulated Expression of SPRY4-IT1 Predicts Poor Prognosis in Colorectal Cancer. Med Sci Monit. 2017; 23:309–14. Epub 2017/01/19. https://doi.org/10.12659/MSM.898369 PMID: 28099409.

24. Shi F, Cai WS, Feng Z, Chen JW, Feng JH, Liu QC, et al. Long non-coding RNA SPRY4-IT1 promotes metastasis and invasion in lung adenocarcinoma. Oncotarget. 2017/04/28. https://doi.org/10.18632/oncota rget.16918

25. Zhou M, Zhang XY, Yu X. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma. Biomed Pharmacother. 2017; 85:348–54. Epub 2016/12/03. https://doi.org/10.1016/j.biopen.2016.11.035 PMID: 27899259.
36. Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015; 151:141–51. Epub 2015/04/08. https://doi.org/10.1016/j.pharmthera.2015.04.002 PMID: 25850036.

37. Wang J, Guo W, Zhou H, Luo N, Nie C, Zhao X, et al. Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death. Oncotarget. 2015; 6(19):17192–205. Epub 2015/05/20. https://doi.org/10.18632/oncotarget.3780 PMID: 25980443.

38. Yang J, Zhao X, Tang M, Li L, Lei Y, Cheng P, et al. The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells. Oncotarget. 2017; 8(14):23492–506. Epub 2017/04/21. https://doi.org/10.18632/oncotarget.15626 PMID: 28423586.